Daniel D Karp

Daniel D Karp

UNVERIFIED PROFILE

Are you Daniel D Karp?   Register this Author

Register author
Daniel D Karp

Daniel D Karp

Publications by authors named "Daniel D Karp"

Are you Daniel D Karp?   Register this Author

43Publications

1232Reads

31Profile Views

A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement.

Cancer Chemother Pharmacol 2018 11 4;82(5):877-885. Epub 2018 Sep 4.

Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3680-yDOI Listing
November 2018

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic.

Oncotarget 2018 Sep 4;9(69):33232-33243. Epub 2018 Sep 4.

Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26075DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145698PMC
September 2018

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

J Clin Oncol 2017 May 13;35(13):1403-1410. Epub 2017 Mar 13.

Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.9352DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559893PMC
May 2017

Innovative Strategies for Decreasing Blood Collection Wait Times for Patients in Early-Phase Cancer Clinical Trials.

J Oncol Pract 2016 07 21;12(7):e784-91. Epub 2016 Jun 21.

The University of Texas MD Anderson Cancer Center, Houston, TX; Medical College of Georgia, Augusta, GA; and Sarah Cannon Research Institute at HealthONE, Denver, CO

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2015.007674DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366248PMC
July 2016

The mu opioid receptor: A new target for cancer therapy?

Cancer 2015 Aug 4;121(16):2681-8. Epub 2015 Jun 4.

Division of Cancer Medicine, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29460DOI Listing
August 2015

Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.

J Clin Oncol 2014 Jul 2;32(19):2059-66. Epub 2014 Jun 2.

Corey J. Langer, University of Pennsylvania; Anthony J. Olszanski, Fox Chase Cancer Center, Philadelphia, PA; Daniel D. Karp, MD Anderson Center, Houston, TX; Rebecca J. Benner, Judith R. Scranton, Pfizer Oncology, Groton, CT; Silvia Novello, University of Turin, Orbassano, Italy; Keunchil Park, Sungkyunkwan University School of Medicine, Seoul, Korea; Maciej Krzakowski, The Maria Sklodowska-Curie Institute of Oncology, Warsaw; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Tony Mok, Chinese University, Hong Kong, Special Administrative Region, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.4932DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067944PMC
July 2014

Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597.

J Clin Oncol 2013 Nov 3;31(33):4179-87. Epub 2013 Sep 3.

Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston; David H. Johnson, University of Texas Southwestern, Dallas, TX; Sandra J. Lee, Dana-Farber Cancer Institute, Boston, MA; Steven M. Keller, Montefiore Medical Center, Bronx, NY; Gail Shaw Wright, Florida Cancer Specialists, New Port Richey, FL; Seena Aisner, University of Medicine and Dentistry of New Jersey/New Jersey Medical School Cancer Institute of New Jersey, Newark, NJ; Steven Alan Belinsky, Lovelace Respiratory Research Institute, Albuquerque, NM; Gary Goodman, Swedish Medical Center Cancer Institute; Gary Goodman, Fred Hutchinson Cancer Research Center, Seattle, WA; Gerald Clamon, University of Iowa, Iowa City, IA; Randolph Marks, Mayo Clinic, Rochester, MN; Worta McCaskill-Stevens, National Cancer Institute, Rockville, MD; Scott M. Lippman, University of California San Diego Cancer Center, San Diego, CA; John Ruckdeschel, Intermountain Healthcare, Salt Lake City, UT; Fadlo R. Khuri, Emory University, Atlanta, GA; Michael R. Johnston, Dalhousie University, Halifax, Nova Scotia; Michael R. Johnston, National Cancer Institute of Canada Clinical Trials Group, Kingston; Gordon Okawara, McMaster University, Hamilton, Ontario; and Eric Frechette, Hopital Laval, Quebec City, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.2173DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821010PMC
November 2013

Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.

Cancer 2010 May;116(10):2409-15

Department of Thoracic Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25076DOI Listing
May 2010

Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases.

Cancer 2009 Jul;115(13):2930-8

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-1402, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.24333DOI Listing
July 2009

The changing face of phase 1 cancer clinical trials: new challenges in study requirements.

Cancer 2009 Apr;115(8):1592-7

Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.24171DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668727PMC
April 2009

Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer.

J Thorac Oncol 2007 Aug;2(8):745-50

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S155608641531305
Publisher Site
http://dx.doi.org/10.1097/JTO.0b013e31811f4719DOI Listing
August 2007

Nonsmall-cell lung cancer: chemoprevention studies.

Semin Thorac Cardiovasc Surg 2003 Oct;15(4):405-20

MD Anderson Cancer Center, Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
October 2003

Down-regulation and antiproliferative role of C/EBPalpha in lung cancer.

Cancer Res 2002 Jan;62(2):528-34

Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
January 2002